DOP018 Effect of adalimumab on extraintestinal manifestations among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA
Travis S.*1, Feagan B.2, Peyrin-Biroulet L.3, Panaccione R.4, Danese S.5, Lazar A.6, Robinson A.7, Thakkar R.7, Pappalardo B.7, Petersson J.7, Bereswill M.6, Chen N.7, Skup M.7
1Oxford University Hospitals, Oxford, United Kingdom 2Robarts Research Institute, London, Canada 3University Hospital of Nancy, Les Nancy, France 4University of Calgary, Calgary, Canada 5Istituto Clinico Humanitas, Milan, Italy 6AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany 7AbbVie Inc., North Chicago, United States
Extraintestinal manifestations (EIMs) are common in patients with ulcerative colitis (UC) and can have a significant impact on patient morbidity and quality of life . We assessed the effect of adalimumab (ADA) therapy on the resolution of EIMs among patients with moderate to severe UC in clinical practice.
INSPIRADA was a single-arm, multi-country, open-label study evaluating the effect of ADA on clinical outcomes, costs of care, treatment satisfaction and work productivity in patients with UC treated according to usual clinical practice. Adults with active UC, Physician's Global Assessment (PGA) ≥2, and Short Inflammatory Bowel Disease Questionnaire ≤45 at baseline (BL) who failed conventional treatment and who experienced rectal bleeding ≤7 days of BL were enrolled. Patients received 160/80 mg ADA at Week 0/2 followed by 40 mg of ADA every other week at Week 4 through Week 26. Patients who did not respond to ADA by Week 8 were to discontinue ADA. Patients who lost response at or after Week 8 could escalate to 40 mg ADA weekly. The presence of EIMs (arthritis, pyoderma gangrenosum, erythema nodosum, and uveitis) were collected in the SCCAI at BL and Weeks 2, 8, and 26. McNemar's test was used to compare the presence of any EIM at Weeks 2, 8, and 26 with BL. In a subset of patients with EIMs at BL, EIM resolution was assessed at Week 2, 8, and 26, defined as no reported EIM at the respective visit; durable EIM resolution at Weeks 2 and 8 was defined as no EIM at the respective visit and subsequent visit(s). Missing data were imputed using last observation carried forward.
Data from 461 patients were analysed. At BL, 88 patients (19.1%) had an EIM. The most commonly reported EIM was arthritis (84 of 88 patients). Pyoderma gangrenosum, erythema nodosum, and uveitis each were reported in <1% of patients at BL and at Weeks 2, 8, and 26. The overall percentage of patients with any EIM decreased significantly (p<0.001) from BL over time: 13.2%, 11.7%, and 10.8% had any EIMs at Weeks 2, 8, and 26, respectively. Similar decreasing percentages were seen for patients with arthritis: 13.0%, 11.7%, and 10.8% at Weeks 2, 8, and 26, respectively. Among those with any EIM at BL, resolution of EIMs increased over time: 39.8%, 52.3%, and 63.6% at Weeks 2, 8, and 26, respectively; durable resolution was 23.9% and 44.3% at Weeks 2 and 8, respectively. Among those with arthritis at BL, resolution rates were 36.9%, 50.0%, and 61.9% at Weeks 2, 8, and 26, respectively; durable resolution was 20.2%, 41.7%, and 61.9%, respectively.
ADA therapy reduced EIMs among patients with moderate to severe UC in usual clinical practice, with EIM resolution in 60% by Week 26.
 Vavricka SR et al, (2015), Inflamm Bowel Dis, 21(8):1982–92